CellSight Technologies
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, CellSight Technologies sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
CellSight Technologies: 8 sponsored US clinical trials, 5 recruiting.
CellSight Technologies sponsors 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit, with 1 trials.
Upper-quartile sponsor footprint
CellSight Technologies sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
NCT06107374
Test-retest Evaluation of [18F]F-AraG PET
NCT06084806
A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
NCT04260256
Imaging Immune Activation in COVID-19
NCT04815096
Imaging Immune Activation in HIV by PET-MR
NCT03684655
Detection of Graft Versus Host Disease With [18F]F-AraG
NCT03367962
Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NCT03129061
Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans
NCT02323893
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 5 |
What is open in the CellSight Technologies pipeline
5 recruiting of 8 indexed (63% open); 3 completed (38%).
Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
CellSight Technologies: open-pipeline peers nationwide
Peers matched on 8 registered trials and 63% open enrollment, not the therapeutic-area sidebar.
CellSight Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 63% open enrollment (± trial volume)
- Canadian Cancer Trials Group · 63% recruiting · 16 trials
- Cook Children's Health Care System · 63% recruiting · 8 trials
- Nurix Therapeutics · 63% recruiting · 8 trials
- Pierre Fabre Medicament · 63% recruiting · 8 trials
Related
What to do with this CellSight Technologies page
8 registered trials is a research-attention snapshot, not an endorsement of CellSight Technologies or any single study.
- 5 of CellSight Technologies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit is the condition CellSight Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
CellSight Technologies pipeline card: 8 registered trials from official public datasets.Report a data error.